Lixian Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lixian Li has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Wanyi Chen
Department of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China
4 shared publications Funan Tan
School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371
2 shared publicationsKaiming Shen
Key Laboratory of Low-Grade Energy Utilization Technologies and Systems, Chongqing University, Chongqing 400044, China
2 shared publicationsMun Yin Chee
School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371
2 shared publicationsShuo Wu
School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371
2 shared publicationsTianli Jin
School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, Singapore 637371
2 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 465
Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral–BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens
Objectives: The co-administration of Bruton’s tyrosine kinase (BTK) inhibitors with antiretroviral drugs is challenging due to potential drug–drug interactions (DDIs). However, clinical trials specifically assessing such DDIs are lacking. We aimed to evaluate DDIs between the BTK inhibitors ibrutinib, zanubrutinib and acalabrutinib with representative antiretroviral drugs and to provide dose adjustment strategies using physiologically based pharmacokinetic (PBPK) models. Methods: PBPK models were developed in PK-Sim software. Model performance was verified by comparing simulated pharmacokinetic parameters and DDI magnitudes with probe drugs (midazolam or maraviroc) with reported clinical data. The validated models were subsequently applied to assess DDIs and explore dose adjustment strategies. Results: The developed PBPK model accurately describes the pharmacokinetics of each drug. Darunavir/ritonavir substantially increased the maximum plasma concentration (Cmax) of ibrutinib, zanubrutinib, and acalabrutinib by 496%, 312%, and 160%, respectively. In contrast, efavirenz reduced Cmax by 43%, 33%, and 37%, respectively, while etravirine caused smaller decreases of 5%, 0%, and 10%. Based on these predictions, recommended dose adjustment strategies include ibrutinib 105 mg once daily, zanubrutinib 40 mg twice daily, and acalabrutinib 50 mg twice daily when co-administered with darunavir/ritonavir or ibrutinib 980 mg once daily, zanubrutinib 240 mg twice daily, and acalabrutinib 150 mg twice daily when co-administered with efavirenz. No dose adjustment is required with etravirine. Conclusions: The PBPK models accurately predicted the in vivo pharmacokinetics of ibrutinib, zanubrutinib, acalabrutinib, and those of the antiretrovirals darunavir/ritonavir, efavirenz, and etravirine, and the DDIs between them. The dose adjustment strategies provided information valuable to the optimization of antineoplastic therapy in HIV-related lymphoma (HRL) patients.
- 10 April 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (4) , 465
Open AccessPhysiologically Based Pharmacokinetic Modeling to Assess Antiretroviral–BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens
Objectives: The co-administration of Bruton’s tyrosine kinase (BTK) inhibitors with antiretroviral drugs is challenging due to potential drug–drug interactions (DDIs). However, clinical trials specifically assessing such DDIs are lacking. We aimed to evaluate DDIs between the BTK inhibitors ibrutinib, zanubrutinib and acalabrutinib with representative antiretroviral drugs and to provide dose adjustment strategies using physiologically based pharmacokinetic (PBPK) models. Methods: PBPK models were developed in PK-Sim software. Model performance was verified by comparing simulated pharmacokinetic parameters and DDI magnitudes with probe drugs (midazolam or maraviroc) with reported clinical data. The validated models were subsequently applied to assess DDIs and explore dose adjustment strategies. Results: The developed PBPK model accurately describes the pharmacokinetics of each drug. Darunavir/ritonavir substantially increased the maximum plasma concentration (Cmax) of ibrutinib, zanubrutinib, and acalabrutinib by 496%, 312%, and 160%, respectively. In contrast, efavirenz reduced Cmax by 43%, 33%, and 37%, respectively, while etravirine caused smaller decreases of 5%, 0%, and 10%. Based on these predictions, recommended dose adjustment strategies include ibrutinib 105 mg once daily, zanubrutinib 40 mg twice daily, and acalabrutinib 50 mg twice daily when co-administered with darunavir/ritonavir or ibrutinib 980 mg once daily, zanubrutinib 240 mg twice daily, and acalabrutinib 150 mg twice daily when co-administered with efavirenz. No dose adjustment is required with etravirine. Conclusions: The PBPK models accurately predicted the in vivo pharmacokinetics of ibrutinib, zanubrutinib, acalabrutinib, and those of the antiretrovirals darunavir/ritonavir, efavirenz, and etravirine, and the DDIs between them. The dose adjustment strategies provided information valuable to the optimization of antineoplastic therapy in HIV-related lymphoma (HRL) patients.
- 9 October 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 330 (Pt 3) , 148144
Enhanced specificity in molecular imprinting: A dual-role chitosan-bentonite substrate coupled with hierarchical monomers for ultrasensitive diclofenac potassium and metabolite enrichment
- 9 October 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 330 (Pt 3) , 148144
Enhanced specificity in molecular imprinting: A dual-role chitosan-bentonite substrate coupled with hierarchical monomers for ultrasensitive diclofenac potassium and metabolite enrichment
- 15 September 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 280, 135659
Circular RNAs in programmed cell death: Regulation mechanisms and potential clinical applications in cancer: A review
- 15 September 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 280, 135659
Circular RNAs in programmed cell death: Regulation mechanisms and potential clinical applications in cancer: A review
- 30 April 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (21) , 10428-10440
NIR and magnetism dual-response multi-core magnetic vortex nanoflowers for boosting magneto-photothermal cancer therapy
Due to the relatively low efficiency of magnetic hyperthermia and photothermal conversion, it is rather challenging for magneto-photothermal nanoagents to be used as an effective treatment during tumor hyperthermal therapy. The advancement of magnetic nanoparticles exhibiting a vortex-domain structure holds great promise as a viable strategy to enhance the application performance of conventional magnetic nanoparticles while retaining their inherent biocompatibility. Here, we report the development of Mn0.5Zn0.5Fe2O4 nanoflowers with ellipsoidal magnetic cores, and show them as effective nanoagents for magneto-photothermal synergistic therapy. Comparative studies were conducted on the heating performance of anisometric Mn0.5Zn0.5Fe2O4 (MZF) nanoparticles, including nanocubes (MZF–C), hollow spheres (MZF–HS), nanoflowers consisting of ellipsoidal magnetic cores (MZF–NFE), and nanoflowers consisting of needle-like magnetic cores (MZF–NFN). MZF–NFE exhibits an intrinsic loss parameter (ILP) of up to 15.3 N h m2 kg−1, which is better than that of commercial equivalents. Micromagnetic simulations reveal the magnetization configurations and reversal characteristics of the various MZF shapes. Additionally, all nanostructures displayed a considerable photothermal conversion efficiency rate of more than 18%. Our results demonstrated that by combining the dual exposure of MHT and PTT for hyperthermia treatments induced by MZF–NFE, BT549, MCF-7, and 4T1 cell viability can be significantly decreased by ∼95.7% in vitro.
- 30 April 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (21) , 10428-10440
NIR and magnetism dual-response multi-core magnetic vortex nanoflowers for boosting magneto-photothermal cancer therapy
Due to the relatively low efficiency of magnetic hyperthermia and photothermal conversion, it is rather challenging for magneto-photothermal nanoagents to be used as an effective treatment during tumor hyperthermal therapy. The advancement of magnetic nanoparticles exhibiting a vortex-domain structure holds great promise as a viable strategy to enhance the application performance of conventional magnetic nanoparticles while retaining their inherent biocompatibility. Here, we report the development of Mn0.5Zn0.5Fe2O4 nanoflowers with ellipsoidal magnetic cores, and show them as effective nanoagents for magneto-photothermal synergistic therapy. Comparative studies were conducted on the heating performance of anisometric Mn0.5Zn0.5Fe2O4 (MZF) nanoparticles, including nanocubes (MZF–C), hollow spheres (MZF–HS), nanoflowers consisting of ellipsoidal magnetic cores (MZF–NFE), and nanoflowers consisting of needle-like magnetic cores (MZF–NFN). MZF–NFE exhibits an intrinsic loss parameter (ILP) of up to 15.3 N h m2 kg−1, which is better than that of commercial equivalents. Micromagnetic simulations reveal the magnetization configurations and reversal characteristics of the various MZF shapes. Additionally, all nanostructures displayed a considerable photothermal conversion efficiency rate of more than 18%. Our results demonstrated that by combining the dual exposure of MHT and PTT for hyperthermia treatments induced by MZF–NFE, BT549, MCF-7, and 4T1 cell viability can be significantly decreased by ∼95.7% in vitro.
- 13 October 2023
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 15 (44) , 17946-17955
Hollow spherical Mn0.5Zn0.5Fe2O4 nanoparticles with a magnetic vortex configuration for enhanced magnetic hyperthermia efficacy
Conventional magnetic nanoagents in cancer hyperthermia therapy suffer from a low magnetic heating efficiency. To address this issue, researchers have pursued magnetic nanoparticles with topological magnetic domain structures, such as the vortex-domain structure, to enhance the magnetic heating performance of conventional nanoparticles while maintaining excellent biocompatibility. In this study, we synthesized hollow spherical Mn0.5Zn0.5Fe2O4 (MZF-HS) nanoparticles using a straightforward solvothermal method, yielding samples with an average outer diameter of approximately 350 nm and an average inner diameter of about 220 nm. The heating efficiency of the nanoparticles was experimentally verified, and the specific absorption rate (SAR) value of the hollow MZF was found to be approximately 1.5 times that of solid MZF. The enhanced heating performance is attributed to the vortex states in the hollow MZF structure as validated with micromagnetic simulation studies. In vitro studies demonstrated the lower cell viability of breast cancer cells (MCF-7, BT549, and 4T1) after MHT in the presence of MZF-HS. The synthesized MZF caused 51% cell death after MHT, while samples of MZF-HS resulted in 77% cell death. Our findings reveal that magnetic particles with a vortex state demonstrate superior heating efficiency, highlighting the potential of hollow spherical particles as effective heat generators for MHT applications.
- 13 October 2023
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 15 (44) , 17946-17955
Hollow spherical Mn0.5Zn0.5Fe2O4 nanoparticles with a magnetic vortex configuration for enhanced magnetic hyperthermia efficacy
Conventional magnetic nanoagents in cancer hyperthermia therapy suffer from a low magnetic heating efficiency. To address this issue, researchers have pursued magnetic nanoparticles with topological magnetic domain structures, such as the vortex-domain structure, to enhance the magnetic heating performance of conventional nanoparticles while maintaining excellent biocompatibility. In this study, we synthesized hollow spherical Mn0.5Zn0.5Fe2O4 (MZF-HS) nanoparticles using a straightforward solvothermal method, yielding samples with an average outer diameter of approximately 350 nm and an average inner diameter of about 220 nm. The heating efficiency of the nanoparticles was experimentally verified, and the specific absorption rate (SAR) value of the hollow MZF was found to be approximately 1.5 times that of solid MZF. The enhanced heating performance is attributed to the vortex states in the hollow MZF structure as validated with micromagnetic simulation studies. In vitro studies demonstrated the lower cell viability of breast cancer cells (MCF-7, BT549, and 4T1) after MHT in the presence of MZF-HS. The synthesized MZF caused 51% cell death after MHT, while samples of MZF-HS resulted in 77% cell death. Our findings reveal that magnetic particles with a vortex state demonstrate superior heating efficiency, highlighting the potential of hollow spherical particles as effective heat generators for MHT applications.
- 6 March 2023
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 25 (14) , 2110-2118
The light-responsive oxidase-like activity of MIL-125-NH2@Pd and its application in the determination of casein phosphopeptides
MIL-125-NH2 with uniform palladium distribution is synthesized through a simple solvothermal method. Based on the excellent light-responsive oxidase-like activity of MIL-125-NH2@Pd, a sensing strategy is developed for the selective detection of CPP.
- 6 March 2023
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 25 (14) , 2110-2118
The light-responsive oxidase-like activity of MIL-125-NH2@Pd and its application in the determination of casein phosphopeptides
MIL-125-NH2 with uniform palladium distribution is synthesized through a simple solvothermal method. Based on the excellent light-responsive oxidase-like activity of MIL-125-NH2@Pd, a sensing strategy is developed for the selective detection of CPP.
- Open Access
- 22 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1321
Stimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This review summarizes current advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in drug delivery. This review focuses on the properties, clinical translation potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and treatment.
- 22 June 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1321
Open AccessStimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment
With advances in nanotechnology, various new drug delivery systems (DDSs) have emerged and played a key role in the diagnosis and treatment of cancers. Over the last two decades, gold nanocages (AuNCs) have been attracting considerable attention because of their outstanding properties. This review summarizes current advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in drug delivery. This review focuses on the properties, clinical translation potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and treatment.